Leanbio, a company providing comprehensive development and manufacturing services for biological products in the pharmaceutical and biopharmaceutical sectors, is adding an additional 20m euros in investment to its plant, currently under construction, in Sant Quirze del Vallès, Barcelona.
Spanning over 3500m2, the facility will house three production lines capable of manufacturing recombinant proteins and antibodies in different expression systems, as well as plasmid DNA and messenger RNA for advanced therapies within the biopharmaceutical sector. It will also include development laboratories, scaling areas, pilot production plants, and quality control.
The project has been selected as a Vanguard Health PERTE initiative, aimed at promoting innovative technological projects in the pharmaceutical sector that also meet strict sustainability criteria.
